Progression on the multiple sclerosis functional composite in multiple sclerosis: What is the optimal cut-off for the three components?

Multiple Sclerosis

Volumn 16, Issue 7, 2010, Pages 862-867

  Bosma, L V A E ^a   Kragt, J J ^a   Brieva, L ^b   Khaleeli, Z ^c   Montalban, X ^b   Polman, Ch ^a   Thompson, Aj ^c   Tintore M ^b   Uitdehaag, B M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

9 Hole Peg Test; multiple sclerosis; Multiple Sclerosis Functional Composite; outcome measurement; Paced Auditory Serial Addition Test; primary progressive; Timed 25 Foot Walk

Indexed keywords

9 HOLE PEG TEST; ARTICLE; DISEASE COURSE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; OUTCOME ASSESSMENT; PACED AUDITORY SERIAL ADDITION TEST; TIMED 25 FOOT WALK; CLINICAL TRIAL; COGNITION; DISABILITY; EUROPE; HAND; MOTOR PERFORMANCE; MULTICENTER STUDY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PSYCHOLOGY; RETROSPECTIVE STUDY; TIME; WALKING;

COGNITION; DISABILITY EVALUATION; DISEASE PROGRESSION; EUROPE; HAND; HUMANS; MOTOR SKILLS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; WALKING;

EID: 77955041173     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510370464     Document Type: Article

References (26)

1. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 ; 343: 898-904.
2. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001 ; 357: 1576-1582.
3. Kappos L., Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 ; 67: 1242-1249.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
5. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
6. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 ; 45: 1268-1276.
7. Comi G., Filippi M., Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001 ; 49: 290-297.
8. Polman CH, OgConnor PW, Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
9. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
10. Hobart J., Freeman J., Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000 ; 123: 1027-1040.
11. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 ; 122: 871-882.
12. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD Quantitative functional measures in MS: what is a reliable change? Neurology 2002 ; 58: 1294-1296.
13. Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH The patientgs perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004 ; 10: 55-60.
14. Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler 2006 ; 12: 594-598.
15. Rudick R., Polman C., Cohen J., et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009 ; 15: 984-997.
16. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231.
17. Bosma L., Kragt J., Brieva L., et al. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009 ; 15: 715-720.
18. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 ; 46: 907-911.
19. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 ; 33: 1444-1452.
20. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001 ; 58: 961-967.
21. Solari A., Radice D., Manneschi L., Motti L., Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005 ; 228: 71-74.
22. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000 ; 54: 802-806.
23. Drake AS, Weinstock-Guttman B., Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010 ; 16: 228-237.
24. Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V., Polman CH Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006 ; 245: 187-194.
25. Bergendal G., Fredrikson S., Almkvist O. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study. Eur Neurol 2007 ; 57: 193-202.
26. Camp SJ, Stevenson VL, Thompson AJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain 2005 ; 128: 2891-2898.